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In mammalian cells, 20 aminoacyl-tRNA synthetases (AARS) catalyze the ligation of amino acids to their cognate
tRNAs to generate aminoacylated-tRNAs. In higher eukaryotes, 9 of the 20 AARSs, along with 3 auxiliary pro
teins, join to form the cytoplasmic multi-tRNA synthetase complex (MSC). The complex is absent in prokaryotes,
but evolutionary expansion of MSC constituents, primarily by addition of novel interacting domains, facilitates
formation of subcomplexes that join to establish the holo-MSC. In some cases, environmental cues direct the
release of constituents from the MSC which enables the execution of non-canonical, i.e., “moonlighting”, func
tions distinct from their essential activities in protein translation. These activities are generally beneficial, but
can also be deleterious to the cell. Elucidation of the non-canonical activities of several AARSs residing in the
MSC suggest they are potential therapeutic targets for cancer, as well as metabolic and neurologic diseases. Here,
we describe the role of MSC-resident AARSs in cancer progression, and the factors that regulate their release from
the MSC. Also, we highlight recent developments in therapeutic modalities that target MSC AARSs for cancer
prevention and treatment.

Introduction
AARSs are essential enzymes that synthesize building blocks of
protein synthesis by ligating amino acids to their cognate tRNAs to form
aminoacylated-tRNAs – essential for decoding genetic information
through protein translation [1–3]. There are 20 cytoplasmic AARSs –
one for each amino acid. The sequence and structure of the catalytic and
anticodon binding domains of AARSs are highly conserved from pro
karyotes to eukaryotes, supporting their early appearance and critical
function in all organisms. Eukaryotic AARSs uniquely harbor novel do
mains appended during evolution, and which exert non-canonical
functions unrelated to translation, but important in multiple complex
pathophysiological processes including inflammation, amino acid
metabolism, tumorigenesis, and neurodegeneration, among others
[4–9]. In humans and other mammals, nine of the cytoplasmic AARSs, in
addition to three scaffolding proteins termed AARS-interacting multi
functional proteins 1–3 (AIMP1–3), form a large ~1.25 MDa MSC
(Fig. 1a,b) [10]. Altered expression or mutation of multiple
MSC-resident AARSs correlates with poor cancer prognosis; in contrast,
the auxiliary AIMP proteins can exhibit anti-tumorigenic activities
[11–13]. The precise physiological function of the MSC remains elusive,

however, a critical role in sequestration of constituents with deleterious
activities in free form has been proposed [14–16]. Thus, besides
expression level, cellular localization of AARSs following release from
the MSC can contribute importantly to physiological and pathological
function. In many cases, pathogenic mutations do not influence AARS
catalytic function, but rather alter their cell localization, and possibly
their non-canonical function involved in tumor promotion, thus
improving their therapeutic suitability as loss-of-function targets [13,
17]. Specific mechanisms of stimulus-dependent release of constituents
are not well understood; however, the recent elucidation of the 3D ar
chitecture of the MSC by cross-linking mass-spectrometry (XL-MS) re
veals specific interaction domains between constituents, and thus can
provide insights into specific sites and domains critical for release [18].
Here, we review our current understanding of the function of MSC
AARSs, and their alternative forms in tumor progression and prevention,
as well as current therapeutic modalities that target them. There is
limited or no data on the relationship of QARS1, IARS1, and RARS1 to
cancer, and these are not discussed in detail.
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MSC-associated AARSs and AIMPs and their role in cancer
progression

factor critical for growth of breast tumors, among others [29–31]. EPRS1
exhibits a non-canonical function as a terminal effector of the
mTORC1-S6K1 axis determining adiposity, and mice bearing an EPRS1
Ser999-to-Ala-loss-of-function mutation are lean . In view of the role of
obesity as a determinant of progression of certain cancer types, e.g.,
breast and ovarian cancer, it will be interesting to test the lean, mutant
EPRS1 mice are resistant to these cancers.

Glutamyl-prolyl-tRNA synthetase (EPRS1)
EPRS1 is an ~170 kDa, bifunctional tRNA synthetase with glutamyltRNA synthetase activity near the N-terminus and proline-tRNA syn
thetase activity at the C-terminus (Fig. 1a). The catalytic domains are
fused with a linker harboring three helix-turn-helix WHEP domains
[19]. The GST-like domain at the N-terminus regulates protein-protein
interactions critical for its association with the MSC [20,21]. A
methylation microarray analysis showed that elevated EPRS1 mRNA
expression in breast cancer patients is associated with an unfavorable
clinical outcome [22]. Likewise, EPRS1 mRNA copy number is associ
ated with increased tamoxifen-resistance and poor prognosis in ER+
breast cancer cells where it induces estrogen receptor expression and
activity [23]. In an alternative mechanism, EPRS1 interaction with
several extra-MSC proteins can contribute to cancer progression. For
example, EPRS1 interacts with Engrailed1, a homeodomain transcrip
tion factor, and disruption of the interaction with synthetic peptides
enhances tumor cell apoptosis [24]. In non-small-cell lung cancer
(NSCLC) cells, DUS2 interaction with EPRS drives cell proliferation,
presumably by enhancing tRNA charging activity [25]. In gastric cancer,
over-expression of EPRS1 induces interaction with SYCL2, in turn acti
vating the WNT/GSK-3β/β-catenin signaling pathway, driving cell pro
liferation and tumor growth [26]. IFN-γ-treatment of macrophages,
induces EPRS1 phosphorylation and release from the MSC to form the
quaternary interferon-γ-activated inhibitor of translation (GAIT) com
plex with NSAP1, ribosomal protein L13a and GAPDH [27,28]. The
complex silences translation of multiple inflammation-related tran
scripts, including vascular endothelial growth factor-A, an angiogenic

Methionyl-tRNA synthetase (MARS1)
MARS1 is an ~100 kDa protein harboring two extra-catalytic do
mains, namely, GST-like and WHEP domains (Fig. 1a) [21]. High level of
MARS1 in breast cancer and NSCLC patients is associated with poor
clinical outcomes; in bile duct adenocarcinoma, enhanced expression of
MARS1 correlates with cell proliferation, migration, and
epithelial-mesenchymal transition [32–34]. At the molecular level,
MARS1-dependent stabilization of CDK4 contributes to breast cancer
progression [35]. Furthermore, by binding and inhibiting ATR, a DNA
repair protein, it reduces DNA damage-induced apoptosis resulting in
colorectal cancer cell growth [35]. A somatic frameshift mutation in
exon 3 of MARS1 was identified in colorectal and gastric cancer, how
ever a potential pathological role has not yet been shown [36]. Finally,
unexpected nucleolar localization of MARS1 regulates ribosomal RNA
production that can contribute to tumorigenesis [37]. MARS1 expres
sion has potential as a diagnostic marker as dual staining of MARS1 and
CD45 has been proposed as a marker for NSCLC [38], and dual immu
nofluorescence staining of MARS1 and AIMP2-DX2 (see below) has
shown utility for detection of lung cancer [39]. The evolutionary addi
tion of the WHEP domain in both MARS1 and EPRS1, combined with the
correlation of both proteins as diagnostic markers in cancer, suggests the
domain has potential as a therapeutic target.
Fig. 1. Mammalian MSC Constituents and Structure.
(a) Domain organization of the MSC-resident AARSs
and auxiliary proteins (AIMPs). Each domain is high
lighted in different color. Catalytic domains (CD, dark
gray), anticodon binding domains (ABD, light gray),
WHEP domains (cyan), lysine-rich N-helical domain
(N-helix, orange), GST-like domains (GST, purple),
leucine zipper (LZ, cyan), N- and C-terminal domains
(N/CTD, light green), vertebrate C-terminal (VC,
green), and EMAP-II (red) are indicated., (b) 3-dimen
sional models of human holo-MSC as obtained from
cross-linking mass spectrometry studies. Ribbon (left)
and space filled (right) models of MSC are illustrated.
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Glutaminyl-tRNA synthetase (QARS1)

Lysyl-tRNA synthetase (KARS1)

Mutations in QARS1, an ~88 kDa protein, are mostly associated with
neurological disorders [40], and reports of cancer-association are
limited. Mass-spectrometric analysis of inactive aggregates of P53 tumor
suppressor, that provides chemoresistance in serous ovarian carcinoma
cells, revealed preferential interaction with QARS1 (among other pro
teins) compared to soluble, active p53, and thus is predicted to
contribute to chemoresistance [41]. Moreover, glutamine-dependent
binding of QARS1 inactivates the pro-apoptotic protein ASK1, and
thus the synthetase might provide the link between glutamine and its
known apoptosis suppressor activity [42]. Information on the role of
QARS1 in cancer progression is limited, and more studies will be
necessary to elucidate its potential role in cancer pathology.

~68 kDa KARS1 is highly over-expressed in multiple cancers
[62–64]. MSC disassociation and membrane re-localization of KARS1 is
associated with dissemination of small groups of cells from colon cancer
spheroids; the KARS1/ERKs/paxillin signaling axis is required for this
dissemination [65,66]. KARS1 promotes cell-cell and cell-extracellular
matrix adhesion required for colon cancer cell migration [67]. Like
wise, KARS1 interaction with laminin receptor 67LR prevents
ubiquitin-dependent degradation of the receptor and promotes cancer
progression [68]. Caspase-8 mediated N-terminus cleavage of KARS1
induces disassociation from the MSC and binding to syntenin which
facilitates exosomic secretion, and ultimately macrophage migration
and inflammation [69]. In spheroids, KARS1 remodels the tumor
microenvironment by inducing M2 macrophage polarization contrib
uting to tumor metastasis [70]. Ser207 phosphorylation of KARS1 by
epidermal growth factor receptor (EGFR), primarily in NSCLC patients
with EGFR mutations, induces nuclear translocation of KARS1, and is
associated with improved mean disease-free survival [71]. In melanoma
cells free KARS1 can generate diadenosine tetraphosphate, i.e., Ap4A,
which binds HINT1, thereby disrupting its interaction with micro
phthalmia transcription factor (MITF), resulting in MITF-dependent
transcription and oncogenic activity [72,73]. Furthermore, KARS1
SNPs are associated with DNA-damage response and increased cancer
occurrence [74,75]. The abundant evidence showing pleiotropic activ
ities of post-translationally modified KARS1 that influence multiple
cancer progression pathways, suggests it is an important MSC AARS
involved in carcinogenesis, and a likely target for therapeutic
intervention

Leucyl-tRNA synthetase (LARS1)
The ~135 kDa LARS1 has been implicated in migration and prolif
eration of lung cancer cells [43]. Recent studies reveal a critical role of
LARS1 in activation of mTORC1, which is upregulated in several cancers
and might present an as-yet unexplored link between the synthetase and
tumorigenesis [44,45]. LARS1, in coordination with Rag GTPase, acts as
a leucine sensor to activate mTORC1 [46–48]. Notch3- and
PHD1-mediated induction of LARS1 directs mTORC1 activation and
adipogenesis, which in turn can contribute to cancer progression [49,
50]. Recent crystallographic elucidation of the structure of mammalian
LARS1 is likely to accelerate the search for low molecular weight in
hibitors for potential anti-cancer therapy [51]. Although, LARS1 has
been studied extensively, a direct association with cancer progression
and studies in primary or patient tissues samples is lacking. Future
studies will determine if LARS1, indeed, is involved in cancer
pathogenesis.

Aminoacyl-tRNA synthase complex-interacting protein 1 (AIMP1)
AIMP1 is an ~34 kDa protein with tumor suppressor activity that
distinguishes it from other MSC constituents. Purified AIMP1 has potent
anti-tumor activity as shown in mouse xenograft models, and inhibition
of cell cycle progression in gastric cancer-bearing mice [76,77]. AIMP1
administration increases expression of the potent tumor-suppressing
cytokines TNF-α and IL-1β [77]. With a sub-clinical dose of paclitaxel,
AIMP1 combination therapy reduces growth of stomach cancer cells and
lung cancer xenografts [76]. The tumor suppressor activity of AIMP1 is
supported by its reduced expression in gastric and colorectal cancer
tissues compared to adjacent normal tissue, as well as under hypoxic
conditions where its high expression is associated with diminished risk
of glioblastoma [78–80]. In pituitary adenomas RARS1 regulates AIMP1
secretion where it exerts potent anti-tumor activity [54]. Proteolytic
cleavage of AIMP1 generates the multi-functional inflammatory cyto
kine endothelial monocyte-activating polypeptide II (EMAP II) [54]
(discussed in detail below). AIMP1 has been associated with poor sur
vival in patients with head and neck squamous cell carcinoma [81]. In
laryngeal squamous cell carcinoma AIMP1, in cooperation with leuko
triene A4 hydrolase (LTA4H), promotes cell proliferation, migration,
and invasion by binding fascin actin-bundling protein 1 [82]. As both
full-length AIMP1 and its cleaved product EMAP II exhibit anti-cancer
activities, strategies have been developed to improve the stability of
the recombinant proteins, primarily by reducing aggregation [83].
AIMP1 influences diverse immune response. It negatively regulates
the expansion of myeloid-derived suppressor cells (MDSCs) involved in
immune suppression in breast tumor-bearing mice, and reduces their
differentiation and induction of Treg cell differentiation [84]. Alterna
tively, AIMP1 stimulates anti-tumorigenic NK cells in a
TNF-α-dependent manner, and TH1 polarization by regulating cytokine
and costimulatory molecule expression as well as p38 MAPK signaling
[85,86]. It stimulates antigen-presenting cells to secrete IL-12 by
increasing NF-κB occupancy on the IL-12 promoter leading to enhanced
TH1 responses [87]. In fact, anti-CD3 single-chain Fv fusion with AIMP1
serves as a DNA adjuvant enhancing TH1 cell-mediated immune

Arginyl-tRNA synthetase (RARS1)
Marked tumorigenic activity of RARS1 has been reported. About a 2fold increase in activity of the ~75 kDa RARS1 was shown in malignant
rat hepatoma cells characterized by increased growth rate compared to
healthy rat liver cells [52]. Reduced expression of microRNAs miR-15a
and miR-16–1 in pituitary adenomas, due to regional deletion, increases
expression of RARS1, which in turn diminishes extracellular secretion of
the tumor suppressor, AIMP1, and accelerates tumor growth [53,54].
The possibility that RARS1 acts as a “sponge” trapping the tumor sup
pressor AIMP1 is a mechanism that needs further investigation. We and
others have shown that RARS1 and AIMP1 interact within the MSC
(Fig. 1b) [18,55] however, the possible role of RARS1 in releasing
AIMP1 from the MSC has not been investigated. Following chromosomal
translocation in nasopharyngeal carcinoma (NPC) fusion of RARS1 with
MAD1L1 induces cancer stem cell-like characteristics driving head and
neck tumor growth [56,57].
Aspartyl-tRNA synthetase (DARS1)
~58 kDa DARS1 was shown to be an oncogene driving progression of
the most prevalent type of renal cell carcinoma, namely, clear cell renal
cell carcinoma (ccRCC). DARS-AS1 is a long noncoding RNA positioned
near the DARS1 gene [58]. DARS-AS1 upregulates DARS1 by seques
tering its inhibitor, miR-194–5p, thereby contributing to malignancy in
ccRCC. Likewise, DARS-AS1 is oncogenic in acute myeloid leukemia
(AML) where it exhibits a negative correlation with the prognostic fac
tor, miR-425, regulating TGF-β expression [59]. DARS-AS1 also accel
erates proliferation of cervical cancer cells via miR-638–5p/JAG1 axis to
regulate Notch pathway [60]. Interestingly, single nucleotide poly
morphisms (SNPs) in DARS1 are associated with altered asparaginase
activity, and might contribute to asparaginase sensitivity in childhood
acute lymphoblastic leukemia [61].
3
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responses against cancer cells [88]. Mouse fibroblasts genetically
modified to express AIMP1 and costimulatory B7.1 exhibit potent
cytotoxic activities against OVA-expressing EG7 tumor cells [89]. The
anti-tumor activity in multiple cell lines, coupled with promising animal
studies, suggests the potential for AIMP1 as a promising target for
anti-cancer therapeutics.

purified from conditioned medium of methycholoanthrene A-induced
murine fibrosarcoma cells, and exhibiting endothelial cell (EC)-acti
vating and monocyte pro-migratory properties [101,102]. EMAP-II
overexpression renders TNF (tumor necrosis factor)-α-resistant soft tis
sue sarcoma sensitive to TNF-α therapy, and is dependent on
TNF-receptor-1 relocalization from Golgi storage pools to the cell
plasma membrane [103–105]. In prostate adenocarcinoma cells,
chemotherapeutic agents induce EMAP II expression, thereby potenti
ating localized activation of host cell effector mechanisms, as well as
anti-angiogenic and pro-apoptotic activities in melanoma lines [106,
107]. EMAP-II binds the EC α5β1 receptor directing its internalization
and interaction with PSMA7, a component of the proteasome degrada
tion pathway that induces HIF-1α degradation [108]. Tumor-bearing
mice treated with a combination of EMAP-II and photodynamic ther
apy (PDT), in which photochemical generation of cytotoxic singlet ox
ygen leads to localized tumor destruction, significantly reduces
tumorigenesis compared to PDT alone [109]. Elevated EMAP-II
expression correlates with improved survival of glioblastoma patients,
and following trans-retinoic acid treatment of squamous carcinoma
cells, is thought to be a mechanism of retinoid chemoprevention [110,
111]. Recombinant EMAP-II therapy in mice retards tumor growth by
targeting vascular endothelium, and possibly inducing cytoskeletal
remodeling [112,113]. EMAP-II increases the blood-tumor barrier
permeability in glioblastoma, and the effectiveness of chemotherapy, by
interacting with the ATP synthase α subunit and altering tight junction
complexes between brain EC [114,115]. In glioblastoma stem cells,
EMAP-II regulates G2/M cell cycle arrest by inhibiting simultaneous
activation of the PI3K/Akt pathway activation and FoxO1 [116,117].
Also in glioblastoma stem cells, combination therapy of EMAP-II with
temozolomide
upregulates
miR-590–3p
and
represses
the
PI3K/AKT/mTOR signaling pathway [118]. In primary uveal mela
noma, expression of EMAP-II correlates with enhanced expression of EC
ICAM-1 which causes macrophage activation and localized vascular
damage [119]. In certain situations, for example in colorectal cancer,
EMAP-II exhibits tumor-protective activity, facilitating tumor evasion of
immune surveillance by inducing apoptosis in activated lymphocytes
and ECs [120–122]. In addition, hypoxia facilitates EMAP-II-dependent
lymphocyte killing and immune evasion [123].
AIMP1 and its proteolytic cleavage product EMAP-II both exhibit
anti-tumorigenic properties; however, there are substantial differences
between their functions. AIMP1, unlike EMAP-II, upregulates proinflammatory chemokines, e.g., IL-8, MIP-1, MIP-2α, MCP-1, and IL-8,
among others [124]. EMAP-II is secreted from apoptotic or necrotic
cells following caspase-mediated cleavage [125], possibly suggesting a
desperate effort by host cells to defend against cancerous cells.

Aminoacyl tRNA synthase complex interacting protein 2 (AIMP2)
AIMP2 is a 38 kDa protein with tumor suppressive activity similar to
AIMP1. Mice heterozygous or homozygous for AIMP2 deletion are
highly susceptible to tumor formation [90]. Oxidative stress induces
AIMP2 disassociation from the MSC and relocalization to the nucleus
where it interacts with FUBP1 (far upstream element binding protein)
resulting in the expression of USP29 (ubiquitin-specific peptidase 29)
which stabilizes p53 by ubiquitin cleavage [91]. AIMP2 expression is
downregulated in gastric and colorectal cancer [78]. In liver cancer
cells, treatment with prostaglandin E2, increases FUSE binding protein
(FBP) and reduces AIMP2 expression, tilting the balance towards higher
FBP expression, in turn inducing c-Myc [92]. TGF-β induces S156
phosphorylation of AIMP2 in HeLa cells, inducing release from the MSC
and nuclear re-localization where it binds Smurf2 protein enhancing
FBP ubiquitination and degradation [93]. AIMP2 regulates the level of
intestinal stem cells (ISC), which in excess can cause colorectal cancer,
by inhibiting the WNT/β-catenin signaling pathway [94]. Following
fusion in nasopharyngeal carcinoma, RARS1-MAD1L1 interacts with
AIMP2, thereby activating the oncogenic FUBP1/c-Myc pathway [57].
Also, AIMP2 has been identified as a hub associated with poor survival
in tongue squamous cell carcinoma [95]. Although, AIMP2 exhibits
robust anti-tumorigenic activities in cell line models, its activity in stem
cell maintenance and RARS1-MADIL1-mediated activation of the
FUBP1/c-Myc pathway indicates its role in cancer pathology still re
mains uncertain.
Aminoacyl tRNA synthase complex interacting protein 3 (AIMP3)
The smallest protein constituent of the MSC, ~20 kDa AIMP3, is a
tumor suppressor that induces the p53 response to DNA damage,
thereby preventing oncogenic stress and cell transformation. Hap
lodeficient AIMP3 cells are more susceptible for transformation by on
cogenes due to altered ATM and ATR kinase activation [96]. Tissue
microarray revealed that expression of AIMP3, like the other AIMPs, is
significantly repressed in several cancer tissues and correlates with pa
tient survival [78,97]. A SNP analysis of Chinese test subjects identified
the rs12199241 allele which reduces AIMP3 expression and is associated
with increased DNA damage, possibly due to reduced activity of the
DNA damage-repair pathway [75]. Likewise, in invasive bladder cancer,
AIMP3 expression is suppressed resulting in increased ionizing radiation
resistance of these cells [97]. Consistent with these findings, AIMP3
knockout mice exhibit significant loss of homologous recombination and
DNA damage, accompanied by acute radiation syndrome-like pheno
type, including hypertrophy of hematopoietic cells, and organ and in
testinal failure [98]. In NSCLC cells, miR-96–5p reduces AIMP3
expression leading to reduced p53 response and enhanced proliferation
and migration of cancer cells in vitro [99]. Evidence for a
pro-tumorigenic role of AIMP3 is uncommon; however, its deletion in
mice is embryonically lethal due to accumulated DNA damage in em
bryonic stem cells and loss of self-renewal and differentiation capability
[100]. It is tempting to speculate that AIMP3 might be involved in
self-renewal of cancer stem cells with deleterious outcome.

AIMP2-DX2
AIMP2-DX2, a splicing variant of AIMP2 lacking exon 2, is patho
logically associated with cancer and is induced by carcinogen treatment,
in contrast to the tumor suppressive activity of the parent AIMP2 [126].
For example, AIMP2-DX2 overexpression is associated with increased
proliferation, migration, and invasion of nasopharyngeal carcinoma
cells [127]. Autoantibodies against AIMP2-DX2 in sera of lung cancer
patients is associated with poor outcomes [128]. In contrast,
down-regulation of AIMP2-DX2 inhibits chemo-resistant ovarian and
lung cancer cell growth [129,130]. In addition to influencing solid
tumor growth, the ratio of AIMP2-DX2/AIMP2 expression correlates
with poor prognosis in hematological cancers [131].
With respect to molecular mechanism, AIMP2-DX2 fails to associate
with the MSC, and competitively binds p53 to interfere with proapoptotic activities of AIMP2 [131]. Its interaction with HSP70 in
creases cell transformation and chemical intervention suppresses cancer
cell growth in vitro and in vivo [132]. Likewise, targeted degradation by
ribozymes efficiently reduces cancer cell growth [133]. AIMP2-DX2
knockdown in mice reduces lung cancer progression by inhibiting the

Variants of MSC constituents and their role in cancer progression
Endothelial-monocyte-activating polypeptide-II (EMAP-II)
EMAP-II is a 22 kDa proteolytically-cleaved fragment of AIMP1, first
4
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AKT1-mTOR-p70S6K1 signaling [134]. AIMP2-DX2 is an example of
how tumor cells take advantage of host cellular machinery to generate
novel proteins supporting their own survival.

TARSL2 is the result of a gene duplication of TARS1 bearing a novel
N-terminal extension that directs inclusion in the MSC [135,136]. Little
is known about the variant, but it has been observed in pediatric brain
tumor cells[137]. Moreover, pathway analysis revealed an association of
TARSL2 with poor bladder cancer outcome [138]. As a newly-identified
MSC constituent, more studies are required to elucidate its
tumor-related function.

non-catalytic, appended domains during evolution, provoking a ques
tion; why are these AARSs not incorporated in the MSC or MSC-like
multi-protein complexes? Many of these extra-MSC AARSs are secre
tory in nature and have anti-tumorigenic properties contrary to the
MSC-associated AARSs [147–153]. Extra-MSC localization might allow
for more rapid or efficient transport across the plasma membrane. Also,
sequestration of MSC-resident AARSs might reduce pro-tumorigenic
activities, unlike the anti-tumorigenic activities of extra-MSC AARSs.
It is possible that during evolution, when the AARSs were gaining
additional domains, the auxiliary proteins selectively sequestered the
pro-tumorigenic/deleterious AARSs into a multi-protein MSC, thereby
regulating their non-canonical functions without affecting their canon
ical function in translation [16].

Function of the MSC

Factors determining constituent release from the MSC

Despite extensive investigation for several decades, the function of
the MSC remains uncertain [139,140]. Inclusion in the MSC can
contribute to stability of constituents [141]. Interaction of the MSC with
ribosomes has been proposed to enhance translation efficiency due to
direct channeling of charged tRNA’s to the emerging polypeptide chain
[142,143]. However, MSC association does not appear to regulate cat
alytic activity of constituent tRNA synthetases, and thus alternative
hypotheses have been suggested [16]. Appendage of domains during
evolution that are absent in prokaryotic AARSs can facilitate
protein-protein interactions, particularly with other MSC constituents,
but also can dictate non-canonical (i.e., moonlighting) functions unre
lated to their primary function in interpretation of the genetic code [19,
144,145]. MSC has been proposed to be a “depot” that sequesters con
stituents that in free form might exhibit detrimental activities [14,15].
In contrast, MSC constituents released in a stimulus-dependent manner
can exhibit condition-specific, beneficial functions; because release does
not require mRNA or protein synthesis, the mechanism has the dual
efficiencies of speed as well as minimal energy requirement.

Post-translational modifications (PTMs)

Threonyl t-RNA synthetase-like protein 2 (TARSL2)

Phosphorylation is the principal PTM that drives release of individ
ual components from the MSC (Fig. 2). In the first known example, IFN-γ
activation of macrophages causes Cdk5- and S6K1-dependent dual
phosphorylation of human EPRS1 at Ser886 and Ser999, thereby stim
ulating its release from the MSC [27,154]. Cdk5 and S6K1 are upregu
lated in multiple cancers, and might contribute to the role of EPRS1 in
tumorigenesis [155,156]. Insulin stimulates phosphorylation of EPRS1
in adipocytes, but its connection to cancer has not been explored [157].
Likewise, EPRS1 Ser990 phosphorylation following viral infection in
duces release from the MSC to inhibit viral replication, but the role of
this modification in cancer is unknown [158]. Ser662 phosphorylation
of MARS1 by GCN2 following UV irradiation induces a conformational
change that causes AIMP3 release from the MSC; subsequent interaction
with p53 in the nucleus induces tumor suppressive activities (Fig. 2)
[159]. In contrast, MARS1 phosphorylation by ERK1/2 at Ser209 and
Ser825 does not induce MSC release, but causes mis-acylation, a phe
nomenon associated with cancer progression [160]. Proteomic analysis
of DARS1 identified phosphorylation sites at Tyr239 and Ser249 and six
acetylation sites at Lys55, 110, 213, 241, 330, and 453, although their
impact on localization is unknown [161]. Likewise, structural studies
identified DARS1 Ser146 phosphorylation in human cells, but the pro
posed role in MSC release has not been validated [162]. Ser207 phos
phorylation of KARS1 induces release from the MSC and relocalization
to the nucleus where it binds and activates microphthalmia-associated
transcription factor (MITF), a -protein implicated in melanoma (Fig. 2)
[163,164]. EGFR-mediated Ser207 phosphorylation of KARS1 in lung
cancer cells and in NSCLC patients has been described, and interestingly,
phospho-KARS1 immunostaining is associated with better prognosis in
these patients [71]. Thr52 phosphorylation causes KARS1
re-localization from the MSC to the plasma membrane where it inhibits
ubiquitin-dependent degradation of the 67-kDa laminin receptor,
thereby enhancing cell migration [68]. DNA damage-mediated phos
phorylation of AIMP2 by JNK causing re-localization from the MSC to
the nucleus where it binds and stabilizes p53 [165]. Similarly, Ser156
phosphorylation of AIMP2 by p38 MAPK in HeLa cells causes release
from the MSC and anti-tumorigenic activity following interaction with
nuclear Smurf2 (Fig. 2) [93]. Likewise, AIMP3 phosphorylation by ERK
is linked to anti-tumorigenic activities, however, its release from the
MSC remains to be explored [96]. Although phosphorylation is the
principal known PTM inducing MSC constituent release, modifications
yet to be determined are worthy of consideration in future studies.

MSC: Pro- or anti-tumorigenic?
As multiple AARSs are upregulated in cancer cells, it is tempting to
speculate it as a pro-tumorigenic consequence of rapid cell-division
requiring highly active translational machinery. However, upregula
tion of only selected AARSs in specific cancers, while maintaining basal
expression in others, argues against this mechanism. The correlation
between MSC release of AARSs (discussed below) and their protumorigenic properties also suggests cancer-causative activity. The
acquisition of appended domains allows the MSC-associated AARSs to
perform both cancer-causing functions and enhanced protein synthesis,
which together can stimulate tumor growth.
Contrary to the MSC-resident AARSs, the auxiliary proteins AIMP1–3
primarily exhibit anti-tumorigenic functions. These conflicting obser
vations ambiguate the overall ex-translational role of the MSC. The
AIMPs lack enzymatic activities and they are generally considered to be
scaffolding proteins involved in the assembly and structure of the large
MSCs found in higher eukaryotes, but not in prokaryotes bearing much
smaller MSCs [10]. Nonetheless, the AIMPs participate in multiple
protein-protein interactions, primarily with appended domains of
MSC-resident AARSs [18]. The important role of AIMPs in AARS
sequestration within the MSC has been shown in studies in which AIMP
knockdown leads to AARS release [141]. Thus, AIMPs exhibit dual
anti-tumorigenic functions – exerted both as extra-MSC activities and by
preventing release of pro-tumorigenic AARSs from the MSC. Thus, the
pro- or anti-tumorigenic activity of the MSC is likely to be stimulus- and
condition-dependent, with the overall activity determined by the spe
cific constituents released.
Apart from the nine MSC-associated AARSs, the eleven extra-MSC
AARSs are associated with several diseases including cancer [4,146].
Similar to MSC-associated AARSs, many extra-MSC AARSs also acquired

Protease-mediated cleavage
Biochemical studies have shown that controlled proteolysis can
generate active mammalian AARS proteoforms (Fig. 2) [142]. Yeast
two-hybrid screen showed calpain-2 interacts not only with LARS1, but
also cleaves other MSC constituents including EPRS1, MARS1, DARS1,
5
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Fig. 2. Environmental Cues Mediate Release of
AARSs from the MSC by Multiple Mechanisms.
Experimentally validated constituents released
from the MSC are depicted. KARS1, EPRS1,
AIMP2, and AIMP3 are released from the MSC
following post-translational modifications, pri
marily phosphorylation. EPRS1, DARS1,
MARS1, KARS1, QARS1, RARS1, and AIMP1
dissociate from the MSC following proteasemediated cleavage. Single nucleotide poly
morphisms mediate MSC release of RARS1 and
KARS1.

QARS1, RARS1, and AIMP1, resulting in generation of fragments that
escape the MSC (Fig. 2) [166]. Similarly, caspase 7-mediated cleavage
releases the EMAP-II domain of AIMP1 that stimulates migration of
mononuclear phagocytes [167]. AIMP1 cleavage by elastase in
apoptotic U937 cells generates p43-derived apoptosis release factor
[168]. N-terminal truncation of QARS1 by calpain prevents MSC
incorporation
and
directs
nuclear
localization
[166].
Caspase-8-mediated cleavage of the N-terminus of KARS1 induces
release from the MSC, secretion via exosomes, and inflammation (Fig. 2)
[69]. Caspase-mediated cleavage at EPRS1 Asp929 in the third WHEP
domain generates neoEPRS1, an N-terminal proteoform of unknown in
vivo function [169].

localization of the mutant remains to be explored [40]. D2G mutation in
the RARS1 N-terminus releases it from the MSC and causes
Pelizaeus-Merzbacher disease (Fig. 2) [174]. In KARS1, P200L and
F263V mutations reduce its affinity for AIMP2 and the MSC, and causes
optic neuropathy (Fig. 2) [175]. The KARS1 P200L mutation site is close
to Ser207, the residue that when phosphorylated causes release from
MSC, consistent with a role of local structure in MSC retention. Other
neurological disease-causing KARS1 mutations including Phe127Leu
and Pro297Ala, reduce dimerization; as KARS1 is present as a dimer in
the MSC, reduced dimerization might influence its localization [176].
Mutations in AIMPs 1 and 2 have been observed in neurodegenerative
diseases, whereas multiple point mutations in AIMP3 (Thr35/Ser40,
Thr76, Thr80, Ser87, Val106 and Arg144) are seen in chronic myeloid
leukemia patients. Few of these mutations reduce the affinity of AIMP3
for ATM but nor for MARS1, but their altered function or localization has
not been investigated [177–179]. Most AARS mutations mentioned here
have been associated with non-cancer pathologies. The adaptation of
whole exome sequencing likely will facilitate identification of additional
AARS mutations, and their potential association with cancer incidence
and progression. Whether the mutations discussed here predispose pa
tient’s cancer is not known, and cell-based studies where similar mu
tation are introduced, for example by CRISPR/Cas9 technology, will

Single nucleotide polymorphisms/point mutations in MSC constituents
Multiple single amino acid changes in EPRS1, LARS1, DARS1, IARS1,
and MARS1 have been reported but MSC localization and their potential
roles in cancer remain to be explored [170–173]. Interestingly, several
mutations in DARS1 (Arg460His, Pro464Leu) that cause hypomyelina
tion with brain stem and spinal cord involvement and leg spasticity were
found that might induce release from the MSC [172]. In the case of
QARS1, R403W mutation causes neurodegenerative disease; however,
6
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clarify MSC localization of these mutant proteins along with additional
functions, and further illuminate the role of MSC release of constituents
on tumorigenic functions.

Anti-cancer therapeutics targeting AARSs
MSC AARSs can stimulate initiation and progression of multiple
cancers, and thus therapeutics targeting these AARSs are under devel
opment [5]. These drugs can target either AARSs catalytic activity
within the tumor or undesirable protein-protein interactions that drive
tumorigenesis. Halofuginone, an inhibitor of the prolyl-tRNA synthetase
catalytic activity of EPRS1 [195] inhibits breast and prostate cancer
metastasis by reducing TGF-β and BMP-regulated pathways, and sensi
tizes lung cancer for chemotherapy by suppressing NRF2 accumulation
[196,197]. Although, a major mechanism of halofuginone function is
inhibition of collagen biosynthesis, it also activates the amino acid
starvation response in cancer cells due to its inhibition of prolyl-tRNA
synthetase activity [195,198,199,200]. As EPRS1 is over-expressed in
many cancers, inhibition of prolyl-tRNA synthetase activity by hal
ofuginone might contribute to its tumor-suppressive activity; however, a
direct link between halofuginone-mediated inhibition of EPRS1 and
reduction in cancer cell growth has not been shown. Xanthoangelol and
4-hydroxyderricin bind EPRS1 and prevent its interaction with SCYL2,
thereby abrogating the WNT/GSK-3β/β-catenin signaling pathway and
reducing patient-derived xenograft tumor growth in mice[26].
Small molecules derived from quinoline, 1,3-benzoxazine, and 1,3oxazine compete with methionine and adenosine binding sites in
MARS1, and are effective in suppressing AF59 and HCT116 cell prolif
eration [201]. Inhibitors of LARS1, e.g., AN2690 and its derivatives,
exhibit anti-tumor activity in U2OS and SKOV3 cells by activating
p21-mediated cell apoptosis [202]. Similarly, the LARS1 inhibitor
BC-LI-0186 at nanomolar concentration exhibits potent anti-tumor ac
tivity against lung cancer cells [203]. Recent studies highlight the role of
LARS1 in mTORC1 activation and competitive inhibitors of LARS1, e.g.,
leucinol
and
leucyladenylate
sulfate
derivatives,
prevent
leucine-mediated activation of mTORC1 [204–209]. Similarly,
BC-LI-0186 prevents LARS1 lysosomal localization and mTORC1 acti
vation by blocking RagD-LARS1 interaction [51]. Small molecule in
hibitors against KARS1, e.g., SL-1910, reduce migration of MDA-MB-231
cells, whereas BC-K_YH16899 inhibits the interaction of KARS1 and 67
kDa laminin receptor, thereby suppressing membrane localization in
cells and metastasis in mouse models [210,211]. Inhibition of
caspase-8-mediated cleavage of KARS1 abrogates its secretion via exo
somes and reduces inflammation [69]. Thiazolo[5,4-b]pyridines
(SL-1910) is a KARS1 inhibitor that reduces cell migration and prevents
tumor metastasis in mice [210]. L-canavanine is a structural analog of
L-arginine that as an RARS1 substrate is competitively incorporated into
nascent proteins. L-canavananyl-containing proteins are less basic than
wild-type, thereby influencing essential protein structures and ionic
interactions, resulting in cell death. Canavanine is specifically seques
tered by the pancreas, and is predicted to be useful as an adjuvant
therapy for pancreatic cancer [212]. Small molecule inhibitors targeting
AIMP2-DX2 mRNA, e.g., BC-DXl01, degrade the transcript and in reduce
AIMP2-DX2 level and tumor size in mice [213]. In lung carcinogenesis,
AIMP2-DX2 induction by oncogenes promotes drug resistance by bind
ing and inhibiting p14/ARF. SLCB050, blocks the interaction between
AIMP2-DX2 and p14/ARF in vitro, and in vivo reduces the viability of
small cell lung cancer cells in a mouse model of K-ras-driven lung
tumorigenesis [214]. BC-DXI-843 is a sulfonamide-based drug that
selectively inhibits AIMP2-DX2 binding to HSP70 resulting in its selec
tive Siah-1-mediated ubiquitination and degradation in lung cancer cells
[132,215]. Pyrimethamine is an anti-parasite drug that also induces
selective, ubiquitin-mediated degradation of AIMP2-DX2, and suggests
potential repurposing as an anti-tumor therapeutic agent [216]. As the
association of AARSs with specific cancer types becomes stronger,
investigation of existing inhibitors and generation of novel therapeutics
is likely to accelerate. Several currently available inhibitors mentioned
here are currently in clinical trials for cancer and other disorders [13].
However, much more basic research and translational development will
be necessary to establish the potential of AARSs as therapeutic targets.

Role of MSC structure in constituent release
The assembly and structure of the MSC can provide important clues
to mechanisms of constituent release. A collection of sub-complexes has
been revealed by biochemical and structural studies, showing key in
teractions, but the role of these complexes in MSC assembly is unclear
[21,55,180]. According to a recent 3-dimensional model, all of the
constituents have substantial surface exposure [18]. The structure is
organized in a way that many constituents have limited interactions
with just a few neighbors, possibly facilitating release. Post-translational
modification, most often phosphorylation can alter the structure of a
constituent or interfere with a critical binding domain interface. The
latter is exemplified by phosphorylation of KARS1 in the domain that
interacts with the N-terminus of AIMP2, thereby inducing a steric clash,
release from the MSC, and subsequent entry into the nucleus [163]. In
nearly all cases only a small fraction of a constituent is released. It is
unclear why only a small amount is released as artificial exclusion of the
entire pool of a constituent from the MSC does not alter protein synthesis
efficiency [16]. Possibly the signaling pathway inducing the
post-translational modification is limiting or transitory. EPRS1 release is
an exception to this principle since at least half is released from the MSC
upon stimulus-dependent phosphoryation[27,157]. In either case, the
amount of a protein released post-modification is sufficient to trigger
robust cellular activities, including effecting cancer progression.
AARSs and immune regulation: a potential link to cancer
development and progression
Immune dysregulation and inflammation are major mechanisms
influencing cancer incidence, progression, and dissemination, and
chronic inflammation due to overactive immune cells is associated with
an increased risk of cancer malignancy [181,182]. Tumor-associated
macrophages in particular have essential roles in tumor progression
[183]. AARSs are influenced by diverse immunological conditions and
stresses within the tumor microenvironment [184]. For example,
TNF-α-induced secretion of KARS1 binds macrophages, feeding forward
to exacerbate TNF-α secretion thus amplifying the inflammatory state
[185]. Similarly, AIMP1 induces macrophage expression of multiple
inflammatory cytokines in a MAPK and NF-κβ-dependent fashion [124].
CD23, a cell-surface receptor for AIMP1 further induces TNF-α secretion
[186]. EMAPII, the secreted proteolytic product of AIMP1, induces an
acute inflammatory response and recruit macrophages [187]. The high
affinity of T-cell receptor (TCR) for microbial peptide:MHC class II
complex upregulates AIMP3 and IL-2R proteins, promoting Th1 cell
differentiation and inflammation [188]. EPRS1, upregulated in multiple
cancers, exhibits an anti-inflammatory function in which it participates
in translational silencing of inflammation-related agents in myeloid
cells, for example VEGFA [27,29]. EPRS1 activates TGF-β/STAT
signaling, and TGF-β induces Th17 cell differentiation a principal
effector of cancer progression [189–191]. Likewise, halofuginone, a
potent inhibitor of the prolyl-tRNA synthetase activity of EPRS1, sup
presses inflammatory response by inhibiting Th17 cell differentiation
[192]. Inhibition of MARS1 suppresses Drosophila inflammatory and
immune response genes and mutations in DARS1 causes leukoence
phalopathy along with spinal cord abnormalities mimicking neuro
inflammatory disease [172,193]. Homozygous mutations in IARS1 cause
very early-onset inflammatory bowel disease associated with T-cell
dysfunction [194]. Many AARSs likely have multi-faceted roles, alone or
in concert with other proteins, driving cancer progression where it can
function as a proto-oncogene by driving specific signaling pathways, and
can also dysregulate the immune environment that by itself can promote
cancer.
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MSC constituents, particularly the AARSs, are essential for cell
viability under normal conditions due to their principal function in
interpretation of the genetic code. However, it is becoming evident that
the same constituents can induce pathology, including cancer progres
sion. Recent appreciation of MSC structure and dynamics is contributing
to our understanding of the mechanisms of activation of MSC constitu
ents, and their potential to exhibit non-canonical moonlighting func
tions. Early and ongoing studies targeting MSC components show
promising anti-tumor outcomes. Continued investigation will be neces
sary to understand the repertoire of functions that the MSC and its
constituents perform, elucidate mechanisms of activation, and develop
novel therapeutics that inhibit its constituent release, activity, or
protein-protein interactions, and ultimately inhibit tumor initiation and
progression.
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